Hikma Pharmaceuticals Share News (HIK)
HIK Share
HIK Share
HIK Share
HIK Share
HIK
HIK Share
HIK Level 2
HIK Live
HIK Broker
HIK Directors
HIK Financial
HIK
HIK Short
HIK
Last checked at -
Fri, 15th Mar 2019 18:32
LONDON (Alliance News) - Hikma Pharmaceuticals PLC said Non-Executive Director Mary Henderson had bought shares worth GBP31,261 in the drugmaker in a transaction on Friday.
Henderson - a non-exec since 2016 - bought 2,000 share at 1,563.05 pence each. Shares in Hikma closed 2.7% higher at 1,598.50 pence on Friday.
The total holding of Henderson after the transaction was not disclosed.
LONDON MARKET MIDDAY: Caution dominates ahead of US nonfarm payrolls
Read moreLONDON MARKET OPEN: Stocks soft, dollar up as US nonfarm payrolls near
Read moreTOP NEWS: Hikma hikes Generics guidance as interim profit swells
Read moreLONDON MARKET PRE-OPEN: LSEG raises Refinitiv cost synergy guidance
Read more
(Sharecast News) - Hikma Pharmaceuticals upgraded full-year guidance for its generics arm and reported a rise in first-half profit and revenue as it hailed a strong performance in both the generics and branded segments, and resilience in the injectables business.
Read moreUK earnings, trading statements calendar - next 7 days
Read moreIN BRIEF: Arecor ends first half of 2021 with solid cash position
Read moreBROKER RATINGS: Barclays upgrades Shell and EnQuest to Overweight
Read moreBROKER RATINGS: Credit Suisse upgrades Legal & General and StanChart
Read more
(Adds background to case, paragraphs 4-10)By Blake BrittainWASHINGTON, June 21 (Reuters) - The U.S. Supreme Court on Monday rejected a bid by an Amarin Corp PLC subsidiary to revive patents on its heart drug Vascepa in a legal battle against gener...
Read moreWASHINGTON, June 21 (Reuters) - The U.S. Supreme Court on Monday rejected a bid by an Amarin Corp PLC subsidiary to revive patents on its heart drug Vascepa in a legal battle against generic drugmakers Hikma Pharmaceuticals PLC and Dr. Reddy's La...
Read more(Sharecast News) - tinyBuild: Berenberg reiterates buy with a target price of 295p.
Read moreBROKER RATINGS: Exane BNP downgrades three property companies
Read moreLONDON MARKET CLOSE: Stocks close out impressive April to end higher
Read moreTOP NEWS: Hikma Pharma confident after promising start to year
Read more
Last checked at